Cellectis receives FDA RMAT designation for blood cancer therapy
Go back to Cellectis receives FDA RMAT designation for blood cancer therapy| (NASDAQ: CLLS) | Delayed: 2.82 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.82 | 52 Week High | $37.55 | |||
| Open | $2.82 | 52 Week Low | $16.35 | |||
| Day High | $2.82 | P/E | N/A | |||
| Day Low | $2.82 | EPS | $0.00 | |||
| Volume | 230 | |||||
